Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Improved Predictability of Diagnosis and Prognosis Using Serum- and Tissue-Derived Extracellular Vesicles From Bulk mRNA Sequencing in Pancreatic Ductal Adenocarcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
    • Subject Terms:
      Carcinoma, Pancreatic Ductal*/genetics ; Carcinoma, Pancreatic Ductal*/diagnosis ; Carcinoma, Pancreatic Ductal*/blood ; Carcinoma, Pancreatic Ductal*/mortality ; Pancreatic Neoplasms*/genetics ; Pancreatic Neoplasms*/diagnosis ; Pancreatic Neoplasms*/blood ; Biomarkers, Tumor*/genetics ; Biomarkers, Tumor*/blood ; MicroRNAs*/genetics ; MicroRNAs*/blood ; RNA, Messenger*/genetics ; Extracellular Vesicles*/metabolism ; Extracellular Vesicles*/genetics; Humans ; Prognosis ; Male ; Female ; Middle Aged ; Aged ; Exosomes/genetics ; Exosomes/metabolism ; Gene Expression Regulation, Neoplastic ; ROC Curve ; Early Detection of Cancer/methods
    • Abstract:
      Background: Early-stage pancreatic ductal adenocarcinoma (PDAC) is frequently misdiagnosed, contributing to its high mortality rate. Exosomal microRNAs (miRNAs) have emerged as potential biomarkers for the early detection of PDAC.
      Aims: This study aimed to evaluate the feasibility of using exosomal miRNAs from PDAC tissues and serum as biomarkers for early detection and prognosis.
      Materials & Methods: Exosomes were isolated from healthy individuals and PDAC patients via tissue and serum samples, then identified by analyzing their particle size and protein content. PDAC-specific exosomal miRNAs were identified using a microRNA array. A large cohort was subsequently recruited to validate these findings. The diagnostic capacity of the identified miRNAs was assessed using the Brier score and area under the curve (AUC). Verified miRNAs were also used to confirm intracellular mRNA change patterns.
      Results: The combination of miR142-3p, miR148a-3p, and CA199 showed a higher AUC (0.747) compared to CA199 alone (0.716) in ROC curve analysis. Gene Ontology (GO) annotations revealed that the two-miRNA panel was associated with multiple oncogenic pathways.
      Discussion: 142-3p and miR148a-3p were identified as specific to PDAC and, when combined with CA199, improved diagnostic accuracy. Their involvement in oncogenic pathways underscores their relevance as diagnostic and prognostic biomarkers.
      Conclusion: MiR142-3p and miR148a-3p, alongside CA199, show promise as non-invasive biomarkers for early detection and prognosis of PDAC, improving diagnostic accuracy.
      (© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
    • References:
      Nat Rev Drug Discov. 2013 May;12(5):347-57. (PMID: 23584393)
      Biol Direct. 2013 Jun 07;8:12. (PMID: 23758897)
      J Extracell Vesicles. 2014 Sep 08;3:. (PMID: 25279113)
      J Neurol Sci. 2016 Jan 15;360:141-52. (PMID: 26723991)
      Lancet. 2020 Jun 27;395(10242):2008-2020. (PMID: 32593337)
      J Extracell Vesicles. 2017 Jul 26;6(1):1348885. (PMID: 28804598)
      Cell Death Dis. 2018 May 29;9(6):644. (PMID: 29844410)
      J Cancer. 2020 Jan 14;11(6):1614-1624. (PMID: 32047567)
      Nature. 2015 Jul 9;523(7559):177-82. (PMID: 26106858)
      Biomark Res. 2023 Sep 13;11(1):80. (PMID: 37705067)
      Mol Cancer. 2020 Jul 27;19(1):117. (PMID: 32713345)
      JAMA. 2021 Sep 7;326(9):851-862. (PMID: 34547082)
      Life Sci. 2021 Jul 1;276:119431. (PMID: 33785332)
      Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. (PMID: 30718832)
      Cancers (Basel). 2023 Aug 30;15(17):. (PMID: 37686618)
      Cancer Med. 2019 Jun;8(6):2810-2822. (PMID: 31006985)
      Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4146-51. (PMID: 22315426)
      Mol Cancer Ther. 2013 Jul;12(7):1266-75. (PMID: 23635652)
      Acta Pharm Sin B. 2020 Jun;10(6):1036-1046. (PMID: 32642410)
      Int J Biol Sci. 2022 Mar 6;18(6):2249-2260. (PMID: 35414782)
      Acta Pharmacol Sin. 2022 Nov;43(11):2946-2955. (PMID: 35388129)
      Br J Cancer. 2015 Jul 14;113(2):275-81. (PMID: 26057451)
      J Biol Chem. 2009 Dec 4;284(49):34211-22. (PMID: 19801663)
      Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22. (PMID: 18228490)
      Nat Commun. 2013;4:2980. (PMID: 24356509)
      Mol Ther Nucleic Acids. 2012 Feb 07;1:e10. (PMID: 23344721)
      Mol Cancer. 2020 Nov 5;19(1):156. (PMID: 33153478)
      Int J Cancer. 2016 Oct 1;139(7):1443-8. (PMID: 27170104)
      J Cell Mol Med. 2020 Nov;24(22):13020-13035. (PMID: 33026174)
      Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):493-502. (PMID: 34002083)
      J Extracell Vesicles. 2021 Dec;10(14):e12175. (PMID: 34918479)
      Mol Cancer. 2022 Jan 17;21(1):19. (PMID: 35039054)
    • Grant Information:
      82002589 the National Natural Science Foundation of China; ZLYNXM202004 Cancer research and translational platform project of Zhongnan Hospital of Wuhan University; 2021BCA114 Grant from the Key Research and Development Program of Hubei Province; WJ2021M255 Research Fund of the Health Commission of Hubei Province
    • Contributed Indexing:
      Keywords: Exosomal miRNA; PDAC; diagnosis; exosome; prognosis
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (MicroRNAs)
      0 (RNA, Messenger)
    • Publication Date:
      Date Created: 20250115 Date Completed: 20250501 Latest Revision: 20250501
    • Publication Date:
      20250501
    • Accession Number:
      PMC11733676
    • Accession Number:
      10.1002/cam4.70538
    • Accession Number:
      39812156